Extending aromatase-inhibitor adjuvant therapy to 10 years

New England Journal of Medicine

Volumn 375, Issue 3, 2016, Pages 209-219

  Goss, P E ^a,b   Ingle, J N ^d   Pritchard, K I ^e   Robert, N J ^j   Muss, H ^k   Gralow, J ^l   Gelmon, K ^f   Whelan, T ^h   Strasser Weippl, K ^m   Rubin, S ⁱ   Sturtz, K ⁿ   Wolff, A C ^o   Winer, E ^b,c   Hudis, C ^p   Stopeck, A ^q   Beck, J T ^r   Kaur, J S ^d   Whelan, K ^g   Tu, D ^g   Parulekar, W R ^g  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MAYO CLINIC   (United States)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g QUEEN S UNIVERSITY   (Canada)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ DALHOUSIE UNIVERSITY   (Canada)

^j Virginia Cancer Specialists   (United States)

^k UNIVERSITY OF NORTH CAROLINA   (United States)

^l UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^m Wilheminen Hospital   (United States)

ⁿ Colorado Cancer Research Program ^*  (United States)

^o JOHNS HOPKINS UNIVERSITY   (United States)

^p MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^q UNIVERSITY OF ARIZONA   (United States)

^r Highlands Oncology Group   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; LETROZOLE; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VITAMIN D; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MINERAL SUPPLEMENTATION; OSTEOPOROSIS; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SURVIVAL RATE; TREATMENT DURATION; VITAMIN SUPPLEMENTATION; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CLINICAL TRIAL; DRUG ADMINISTRATION; INCIDENCE; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; POSTMENOPAUSE; RECURRENT DISEASE; SECONDARY PREVENTION;

AGED; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NITRILES; POSTMENOPAUSE; QUALITY OF LIFE; RECURRENCE; SECONDARY PREVENTION; TRIAZOLES;

EID: 84979701285     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1604700     Document Type: Article

References (15)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2001;1:CD000486.
2. Gray RG, Rea D, Handling K, et al. aTTom (adjuvant Tamoxifen-To offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer - preliminary results. J Clin Oncol 2008;26:Suppl 10s:513. abstract.
3. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805-16.
4. Strasser-Weippl K, Badovinac-Crnjevic T, Fan L, Goss PE. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer. Breast 2013;22:Suppl 2:S171-5.
5. Tu D. Minimization procedure. In: Chow SC, ed. Encyclopedia of biopharmaceutical statistics. 2nd ed. New York: Marcel Dekker, 2003:614-8.
6. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
7. Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161-75.
8. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 health survey manual and interpretation guide. Boston: The Health Institute, New England Medical Center, 1993.
9. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-92.
10. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in post-menopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
11. Jakesz R, Samonigg H, Greil R, et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). Proc Am Soc Clin Oncol 2005;23:Suppl 16S:527. abstract.
12. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:3629-35.
13. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008;26:556-62.
14. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602-6.
15. Ziller V, Kalder M, Albert US, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009;20:431-6.